DK3445788T3 - Novel bispecific polypeptides against cd137 - Google Patents

Novel bispecific polypeptides against cd137 Download PDF

Info

Publication number
DK3445788T3
DK3445788T3 DK17718928.9T DK17718928T DK3445788T3 DK 3445788 T3 DK3445788 T3 DK 3445788T3 DK 17718928 T DK17718928 T DK 17718928T DK 3445788 T3 DK3445788 T3 DK 3445788T3
Authority
DK
Denmark
Prior art keywords
polypeptides against
novel bispecific
bispecific polypeptides
novel
polypeptides
Prior art date
Application number
DK17718928.9T
Other languages
Danish (da)
English (en)
Inventor
Eva Dahlén
Peter Ellmark
Christina Furebring
Per Norlén
Anna Säll
Laura Von Schantz
Niina Veitonmäki
Sara Fritzell
Laura Varas
Jessica Petersson
Original Assignee
Alligator Bioscience Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alligator Bioscience Ab filed Critical Alligator Bioscience Ab
Application granted granted Critical
Publication of DK3445788T3 publication Critical patent/DK3445788T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
DK17718928.9T 2016-04-22 2017-04-24 Novel bispecific polypeptides against cd137 DK3445788T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201607046 2016-04-22
PCT/EP2017/059656 WO2017182672A1 (en) 2016-04-22 2017-04-24 Novel bispecific polypeptides against cd137

Publications (1)

Publication Number Publication Date
DK3445788T3 true DK3445788T3 (en) 2022-04-11

Family

ID=58609424

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17718928.9T DK3445788T3 (en) 2016-04-22 2017-04-24 Novel bispecific polypeptides against cd137

Country Status (14)

Country Link
US (2) US20190169308A1 (cg-RX-API-DMAC7.html)
EP (1) EP3445788B1 (cg-RX-API-DMAC7.html)
JP (2) JP2019523630A (cg-RX-API-DMAC7.html)
KR (1) KR102426765B1 (cg-RX-API-DMAC7.html)
CN (1) CN109195994A (cg-RX-API-DMAC7.html)
AU (1) AU2017252233A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018071612A2 (cg-RX-API-DMAC7.html)
CA (1) CA3021618A1 (cg-RX-API-DMAC7.html)
DK (1) DK3445788T3 (cg-RX-API-DMAC7.html)
ES (1) ES2910365T3 (cg-RX-API-DMAC7.html)
IL (1) IL262482A (cg-RX-API-DMAC7.html)
MX (1) MX2018012897A (cg-RX-API-DMAC7.html)
RU (1) RU2018139339A (cg-RX-API-DMAC7.html)
WO (1) WO2017182672A1 (cg-RX-API-DMAC7.html)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE054526T2 (hu) 2014-10-29 2021-09-28 Bicyclerd Ltd MT1-MMP-ra specifikus biciklusos peptid ligandumok
TW201806972A (zh) 2016-05-27 2018-03-01 美商艾伯維生物醫療股份有限公司 雙特異性結合蛋白
AU2017283181B2 (en) 2016-06-20 2024-08-15 F-Star Therapeutics Limited Binding molecules binding PD-L1 and LAG-3
CA3027302A1 (en) 2016-06-20 2017-12-28 F-Star Beta Limited Binding members(1)
KR20240017129A (ko) 2016-07-14 2024-02-06 젠맵 에이/에스 Cd40 및 cd137에 대한 다중특이적 항체
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
UA127449C2 (uk) * 2016-09-23 2023-08-30 Мерус Н.В. Зв'язувальна молекула, яка модулює біологічну активність, що експресується клітиною
TW202515920A (zh) 2017-04-11 2025-04-16 美商因荷布瑞克斯生物科學公司 具有經受限cd3結合的多重特異性多肽構築體及使用其之方法
JP7297672B2 (ja) 2017-04-13 2023-06-26 アジェナス インコーポレイテッド 抗ｃｄ１３７抗体およびその使用方法
EP3655439A1 (en) * 2017-07-20 2020-05-27 Aptevo Research and Development LLC Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
KR20250020679A (ko) 2017-08-04 2025-02-11 젠맵 에이/에스 Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
US11261214B2 (en) 2017-08-04 2022-03-01 Bicycletx Limited Bicyclic peptide ligand specific for CD137
JP2021502810A (ja) 2017-11-13 2021-02-04 クレッシェンド、バイオロジックス、リミテッドＣｒｅｓｃｅｎｄｏ Ｂｉｏｌｏｇｉｃｓ Ｌｉｍｉｔｅｄ Ｃｄ１３７およびｐｓｍａに結合する分子
WO2019121906A1 (en) 2017-12-19 2019-06-27 F-Star Beta Limited Specific pd-l1 binding sequences inserted in a ch3 domain
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
CN109970865B (zh) * 2017-12-28 2022-10-04 上海细胞治疗研究院 一种cd137双向激活共刺激分子受体及其用途
US10875894B2 (en) 2018-02-23 2020-12-29 Bicycletx Limited Multimeric bicyclic peptide ligands
CN120795158A (zh) 2018-03-12 2025-10-17 健玛保 抗体
MX2020010444A (es) * 2018-04-04 2021-01-08 Bicycletx Ltd Complejos de péptidos bicíclicos en heterotándem.
TW202010757A (zh) 2018-04-11 2020-03-16 美商英伊布里克斯公司 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
WO2019232323A1 (en) * 2018-05-31 2019-12-05 Board Of Regents, The University Of Texas System Bi-specific antibodies and use thereof
WO2019234187A1 (en) * 2018-06-06 2019-12-12 Leadartis, S.L. Trimeric polypeptide complexes and uses thereof
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811415D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811404D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
TWI861005B (zh) 2018-07-12 2024-11-11 英商英沃克斯製藥有限公司 結合pd-l1及cd137的抗體分子
GB201811450D0 (en) * 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
EP3820898B1 (en) 2018-07-12 2025-09-03 invoX Pharma Limited Antibody molecules that bind cd137 and ox40
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
WO2020023553A1 (en) 2018-07-24 2020-01-30 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
EP3864051A4 (en) * 2018-10-10 2022-11-23 Zymeworks Inc. ANTIBODY CONSTRUCTS THAT BIND 4-1BB AND TUMOR-ASSOCIATED ANTIGENS AND THEIR USES
TW202506736A (zh) * 2018-10-11 2025-02-16 美商因荷布瑞克斯生物科學公司 5t4單域抗體及其治療性組合物
WO2020083277A1 (zh) * 2018-10-22 2020-04-30 上海一宸医药科技有限公司 一种双特异性抗体
WO2020107715A1 (en) * 2018-11-30 2020-06-04 Abl Bio Inc. Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
WO2020127374A2 (en) * 2018-12-17 2020-06-25 Alligator Bioscience Ab Novel polypeptides
GB201820556D0 (en) * 2018-12-17 2019-01-30 Alligator Bioscience Ab Novel polypeptides
EP3898681A2 (en) * 2018-12-17 2021-10-27 Alligator Bioscience AB Polypeptides
CN113195006A (zh) * 2018-12-21 2021-07-30 锕医药有限责任公司 用于治疗癌症的放射免疫疗法和免疫检验点疗法的联合疗法
EP3897849A1 (en) 2018-12-21 2021-10-27 BicycleTx Limited Bicyclic peptide ligands specific for pd-l1
TWI793395B (zh) * 2019-01-25 2023-02-21 大陸商信達生物製藥（蘇州）有限公司 結合ｐｄ-ｌ１和ｏｘ４０的雙特異性抗體
GB201905100D0 (en) * 2019-04-10 2019-05-22 Antibody Innovation Ltd Polypeptides and methods of use
WO2020225577A1 (en) 2019-05-09 2020-11-12 Bicycletx Limited Bicyclic peptide ligands specific for ox40
WO2021020845A1 (en) * 2019-07-26 2021-02-04 Abl Bio Inc. Anti-egfr/anti-4-1bb bispecific antibody and use thereof
CA3147423A1 (en) * 2019-07-26 2021-02-04 Abl Bio Inc. Anti-her2/anti-4-1bb bispecific antibody and use thereof
TWI862640B (zh) * 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
CN112592404B (zh) * 2019-09-20 2023-07-25 上海交通大学医学院 抗体活性改造及其筛选方法
EP4592309A3 (en) * 2019-10-03 2025-10-22 BicycleTx Limited Heterotandem bicyclic peptide complexes
EP3816185A1 (en) 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
WO2021101346A1 (en) * 2019-11-21 2021-05-27 Dong-A St Co., Ltd. Anti-ror1/anti-4-1bb bispecific antibodies and uses thereof
WO2021137231A1 (en) 2019-12-31 2021-07-08 Kahr Medical Ltd. Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same
WO2021137230A1 (en) 2019-12-31 2021-07-08 Kahr Medical Ltd. Methods of culturing t cells and uses of same
CN115244175A (zh) 2020-01-07 2022-10-25 得克萨斯大学体系董事会 用于癌症治疗的改进的人甲硫腺苷/腺苷消耗酶变体
CN115190889A (zh) * 2020-02-28 2022-10-14 上海复宏汉霖生物技术股份有限公司 抗cd137构建体、多特异性抗体及其用途
KR20220145859A (ko) * 2020-02-28 2022-10-31 상하이 헨리우스 바이오테크, 인크. 항cd137 작제물, 다중 특이적 항체 및 그 용도
CA3146977A1 (en) * 2020-04-15 2021-10-21 Zymeworks Inc. Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof
EP4153316A1 (en) 2020-05-19 2023-03-29 Boehringer Ingelheim International GmbH Binding molecules for the treatment of cancer
WO2022002063A1 (zh) * 2020-06-30 2022-01-06 和铂医药(上海)有限责任公司 一种4-1bb结合蛋白及其应用
US12122845B2 (en) 2020-08-07 2024-10-22 Eutilex Co., Ltd. Anti-HER2/anti-4-1BB bispecific antibodies and uses thereof
AU2021374803A1 (en) * 2020-11-03 2023-06-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Target-cell restricted, costimulatory, bispecific and bivalent anti-cd28 antibodies
WO2022158889A1 (en) * 2021-01-25 2022-07-28 Yuhan Corporation Methods for purifying an anti-4-1bb/anti-her2 bispecific antibody
CN118234750A (zh) * 2021-09-02 2024-06-21 纪念斯隆-凯特琳癌症中心 抗cd33抗体和其用途
JP2024537322A (ja) * 2021-10-12 2024-10-10 コンセプト トゥー メディシン バイオテック カンパニー， リミテッド 単一ドメイン４－１ｂｂ抗体
WO2023174521A1 (en) * 2022-03-15 2023-09-21 Genmab A/S Binding agents binding to epcam and cd137
WO2024051752A1 (en) * 2022-09-06 2024-03-14 I-Mab Biopharma Co., Ltd. Multispecific constructs and uses thereof
EP4592317A1 (en) * 2022-09-22 2025-07-30 ABlink Biotech Co., Ltd. Anti-4-1bb nanobody, preparation therefor, and use thereof
WO2024085166A1 (ja) * 2022-10-19 2024-04-25 アステラス製薬株式会社 がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用
KR20240095012A (ko) * 2022-11-29 2024-06-25 (주) 테라베스트 Cd137 세포외 도메인을 포함하는 융합단백질, 이를 발현하는 면역세포 및 이의 용도
JP2025542406A (ja) * 2022-12-30 2025-12-25 アブクロン・インコーポレイテッド Ｃｄ１３７に特異的に結合するアフィボディ及びその用途
WO2025035107A2 (en) * 2023-08-09 2025-02-13 Curadh Mtr, Inc. Trophoblast glycoprotein antibody compositions and methods of use
WO2025056180A1 (en) * 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
EP2161286A1 (en) * 1999-11-18 2010-03-10 Oxford Biomedica (UK) Limited Antibodies
AU2001236621B2 (en) * 2000-02-01 2006-06-15 Mycenax Biotech Inc. Cd40-binding apc-activating molecules
EP1272647B1 (en) 2000-04-11 2014-11-12 Genentech, Inc. Multivalent antibodies and uses therefor
TW200616662A (en) 2004-09-10 2006-06-01 Wyeth Corp Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2663580B1 (en) * 2011-01-10 2016-12-07 CT Atlantic Ltd. Combination therapy including tumor associated antigen binding antibodies
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
US20130058936A1 (en) 2011-08-23 2013-03-07 Peter Bruenker Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
CA2846432A1 (en) * 2011-09-23 2013-03-28 Amgen Research (Munich) Gmbh Bispecific binding molecules for 5t4 and cd3
WO2014116846A2 (en) * 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
CN106459206B (zh) * 2014-04-07 2024-06-07 中外制药株式会社 免疫活化抗原结合分子
US20150307620A1 (en) * 2014-04-16 2015-10-29 University Of Connecticut Linked immunotherapeutic agonists that costimulate multiple pathways
CN105233291A (zh) * 2014-07-09 2016-01-13 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
PT3242890T (pt) * 2015-01-08 2019-12-10 Genmab As Agentes de ligação agonistas do recetor de tnf
EP3245227A4 (en) * 2015-01-14 2018-07-25 Compass Therapeutics LLC Multispecific immunomodulatory antigen-binding constructs
IL255767B2 (en) * 2015-05-21 2024-04-01 Alligator Bioscience Ab Novel polypeptides
US11459394B2 (en) * 2017-02-24 2022-10-04 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
EP3655439A1 (en) 2017-07-20 2020-05-27 Aptevo Research and Development LLC Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods

Also Published As

Publication number Publication date
MX2018012897A (es) 2019-01-17
WO2017182672A1 (en) 2017-10-26
EP3445788B1 (en) 2022-01-19
IL262482A (en) 2018-12-31
EP3445788A1 (en) 2019-02-27
KR20180135454A (ko) 2018-12-20
AU2017252233A1 (en) 2018-11-15
CN109195994A (zh) 2019-01-11
KR102426765B1 (ko) 2022-07-29
JP2022058338A (ja) 2022-04-12
RU2018139339A3 (cg-RX-API-DMAC7.html) 2020-09-28
RU2018139339A (ru) 2020-05-22
CA3021618A1 (en) 2017-10-26
ES2910365T3 (es) 2022-05-12
BR112018071612A2 (pt) 2019-02-19
US12173082B2 (en) 2024-12-24
US20190169308A1 (en) 2019-06-06
JP2019523630A (ja) 2019-08-29
US20220213213A1 (en) 2022-07-07

Similar Documents

Publication Publication Date Title
DK3445788T3 (en) Novel bispecific polypeptides against cd137
IL255767A (en) New polypeptides
ZA201802261B (en) Polypeptides
IL254577A0 (en) polypeptides
GB201611530D0 (en) Novel polypeptides
GB201508337D0 (en) Novel peptides
ZA201704366B (en) Il-17a-binding polypeptides
SG11201706882VA (en) Polypeptides
SG10202109234YA (en) Novel peptide
GB201607534D0 (en) Peptides
GB201520539D0 (en) Peptides
GB201707139D0 (en) Polypeptides
GB201604468D0 (en) Peptides
GB201520536D0 (en) Peptides
GB201520543D0 (en) Peptides
GB201619652D0 (en) Novel polypeptides
GB201506316D0 (en) Novel peptide
GB201520541D0 (en) Peptides
GB201607535D0 (en) Peptides
GB201520542D0 (en) Peptides
GB201506092D0 (en) Novel material
IL246533A0 (en) new proteins
HK40004686A (en) Novel bispecific polypeptides against cd137
GB201717958D0 (en) Novel polypeptides
GB201706915D0 (en) Novel polypeptides